{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Treatments for Relapsed Hematologic Malignancies After alloHCT

Activity Steps

Purpose of Activity

To provide information on new therapeutic options for relapsed hematologic malignancies after allogenic hematopoietic cell (alloHCT) transplantation.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Identify new pharmacologic immunotherapy agents used in the treatment of relapsed hematologic malignancies after alloHCT transplantation.
  2. Examine potential adverse and serologic effects of immune checkpoint inhibitors and tyrosine kinase inhibitors.
Price: $12.95


  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Test Code: OT1018
Published: Oct 2018
Expires: 9/3/2021
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Jacqueline S. Garcia, MD; Matthew S. Davids, MD, MMSc
Categories: Oncology